Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor in adults with primary sclerosing cholangitis
2024-511370-72-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Elafibranor with Placebo (2 arms). Planned start Mar 2023; status: authorised.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2024-511370-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511370-72-00.